Dr. Schoffski Discusses Findings from the CREATE Study

Patrick Schöffski, MD, MPH, head of the Department of General Medical Oncology at the University Hospital Leuven, discusses findings from the EORTC 90101/CREATE study presented during the 2018 AACR Annual Meeting.

The phase II prospective precision medicine CREATE trial investigated crizotinib (Xalkori) in patients with advanced, inoperable inflammatory myofibroblastic tumors with or without ALK alterations. Among 12 eligible and evaluable ALK-positive patients, 6 achieved a confirmed partial or complete response, 1 a non-confirmed partial response. Five patients had stable disease as best response.

In the ALK-positive population, there was an overall response rate of 50%, with a disease control rate of 100%. In those with ALK-negative disease, there were sporadic responses and disease stabilization, notes Schöffski. Common crizotinib-related adverse events were nausea (55%), fatigue (45%), blurred vision (45%), vomiting (35%), diarrhea (35%).

<<< 2018 AACR Annual Meeting